Background Mitoxantrone plus prednisone reduces pain and improves the quality of life in
men with advanced, hormone-refractory prostate cancer, but it does not improve survival. We …

Context In men who develop an elevated serum prostate-specific antigen level (PSA) after
having undergone a radical prostatectomy, the natural history of progression to distant …

Background The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-binding
domain, which is the target of enzalutamide and abiraterone, but remains constitutively …

Background Androgen-deprivation therapy (ADT) has been the backbone of treatment for
metastatic prostate cancer since the 1940s. We assessed whether concomitant treatment with …

Purpose To update eligibility and outcome measures in trials that evaluate systemic treatment
for patients with progressive prostate cancer and castrate levels of testosterone. Methods …

To test the hypothesis that maximal androgen blockade improves the effectiveness of the
treatment of prostatic cancer, we conducted a randomized, double-blind trial in patients with …

Purpose The TAX 327 study compared docetaxel administered every 3 weeks (D3), weekly
docetaxel (D1), and mitoxantrone (M), each with prednisone (P), in 1,006 men with …

ContextThe natural history of biochemical recurrence after radical prostatectomy can be long
but variable. Better risk assessment models are needed to identify men who are at high risk …

Background Combined androgen blockade for the treatment of metastatic prostate cancer
consists of an antiandrogen drug plus castration. In a previous trial, we found that adding the …

PURPOSE: Prostate-specific antigen (PSA) is a glycoprotein that is found almost exclusively
in normal and neoplastic prostate cells. For patients with metastatic disease, changes in …